Arbutus Biopharma Corporation (NASDAQ:ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV).

Biotechnology

Arbutus Biopharma

Michael McElhaugh

Ganapati Reddy Pamulapati

Shannon Briscoe

Michael Child

Catherine Coffey Ross

Karen Sims

Michael J. Sofia Phd

Elizabeth Howard

David C. Hastings

Scientific and Research Team

Clinical Operations Team

Finance and Accounting

Leadership Team

Teams at Arbutus Biopharma

Scientific and Research Team

Clinical Operations Team

Finance and Accounting

Leadership Team